Top Markets
#1 Palladium Network Palladium Network +27.91%
#2 Ankr Network Ankr Network +25.74%
#3 Siren Siren +22.87%
#4 Status Status +13.69%
#5 BankrCoin BankrCoin +12.46%
#6 ICON ICON +11.78%
#7 WAX WAX +8.31%
#8 Wiki Cat Wiki Cat +7.36%
#9 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.04%
#10 would would +6.48%
Coin of the day
Palladium Network Palladium Network
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
Classement en actions #17992
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Prix de l'action
$1.69
Dernière synchronisation: 2026-09-02
Capitalisation boursière
$216.83M
Changement (1 jour)
3.38%
Changement (1 an)
-66.03%
Pays
US
Échange Organogenesis Holdings Inc. (ORGO)

Catégorie

Healthcare
Ratio P/E pour Organogenesis Holdings Inc. (ORGO)
Ratio P/E au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Organogenesis Holdings Inc., le ratio P/E actuel (TTM) est de 0. À la fin de l’année 2026, le P/E de l’entreprise était de 0.
Historique du ratio P/E pour Organogenesis Holdings Inc. de 2026 à 2026
Ratio P/E à la fin de chaque année
Année Ratio P/E Changez
Pas assez de données pour les dates fournies.
Ratio P/E pour des entreprises similaires ou concurrentes
Entreprise P/E Ratio Différence du P/E Ratio Pays
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 38.38 -
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Comment lire un P/E ratio ?

Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.

Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.

Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.